1. Home
  2. INAB vs AIRE Comparison

INAB vs AIRE Comparison

Compare INAB & AIRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IN8bio Inc.

INAB

IN8bio Inc.

HOLD

Current Price

$1.48

Market Cap

13.7M

Sector

Health Care

ML Signal

HOLD

Logo reAlpha Tech Corp.

AIRE

reAlpha Tech Corp.

HOLD

Current Price

$1.94

Market Cap

11.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
INAB
AIRE
Founded
2016
2021
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.7M
11.5M
IPO Year
2020
2023

Fundamental Metrics

Financial Performance
Metric
INAB
AIRE
Price
$1.48
$1.94
Analyst Decision
Strong Buy
Buy
Analyst Count
1
3
Target Price
$6.00
$1.30
AVG Volume (30 Days)
50.0K
72.8K
Earning Date
05-11-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
60.34
EPS
N/A
N/A
Revenue
N/A
$4,518,498.00
Revenue This Year
N/A
$129.06
Revenue Next Year
N/A
$83.72
P/E Ratio
N/A
N/A
Revenue Growth
N/A
376.42
52 Week Low
$1.17
$0.14
52 Week High
$2.73
$3.98

Technical Indicators

Market Signals
Indicator
INAB
AIRE
Relative Strength Index (RSI) 46.82 45.56
Support Level $1.34 $1.89
Resistance Level $1.85 $2.77
Average True Range (ATR) 0.08 0.19
MACD -0.00 -0.05
Stochastic Oscillator 60.91 12.30

Price Performance

Historical Comparison
INAB
AIRE

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

About AIRE reAlpha Tech Corp.

ReAlpha Tech Corp is a real estate technology company. The group is engaged in an end-to-end commission-free homebuying platform. It develops and utilizes its artificial intelligence-focused technology stack to empower retail investor participation in short-term rental properties, which are real estate units listed for a rental term. It provides short-term rental investment opportunities to everyday investors. The company has developed technologies and tools that allow for the analysis of short-term rental properties using AI to provide insight into that property's potential profitability and ways to increase such profitability. The company's reportable segments are Homebuying Services and the Technology Services segment.

Share on Social Networks: